Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Otis Worldwide Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Otis Worldwide Corp trades at $73.33 (market cap $28.05B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.33% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OTIS | |
|---|---|---|
Market Cap | $39.89B | $28.05B |
Sector | Health | Industrials |
52-Week High | $491.22 | $101.07 |
52-Week Low | $278.09 | $69.34 |
Enterprise Value | $38.15B | $35.43B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Otis Worldwide trades at $73.09, up 1.51% today, amid a bearish technical signal despite neutral oscillators. The company reported mixed quarterly earnings, with Q1 2026 missing estimates, but maintains steady revenue growth and a 10.11% net income margin. Recent news highlights strategic modernization projects and a 5% dividend increase, while analyst consensus remains cautiously optimistic with a $94 price target.
The stock presents a value opportunity with a P/E of 19.44 below historical averages, but faces headwinds from China exposure and margin pressure. Upside potential exists if earnings rebound, though high debt and competitive risks warrant caution for investors seeking stable industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
